0000891293-15-000072.txt : 20151223 0000891293-15-000072.hdr.sgml : 20151223 20151223191339 ACCESSION NUMBER: 0000891293-15-000072 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151223 FILED AS OF DATE: 20151223 DATE AS OF CHANGE: 20151223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Plunkett Matthew CENTRAL INDEX KEY: 0001557551 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12465 FILM NUMBER: 151306739 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE, SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2015-12-23 0 0000891293 CTI BIOPHARMA CORP ctic 0001557551 Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE WA 98121 0 1 0 0 EVP, Chief Business Officer Performance Rights 0 2015-12-23 4 D 0 253438 0 D Common Stock 253438 0 D Employee Stock Option (Right to Buy) 1.24 2015-12-23 4 A 0 1400000 0 A 2025-12-23 Common Stock 1400000 1400000 D In a Form 4 filed on March 22, 2013, the reporting person reported the acquisition of the number of performance rights identified in the table above that related to the issuer's achievement of a market capitalization goal. That award no longer represents the right to receive shares of the issuer's common stock. Instead, if the applicable performance goal is achieved by December 31, 2016, the reporting person will be entitled to the grant of a stock option with respect to the same number of shares that would have been issued to the reporting person upon achievement of the goal under the original terms of the award. The option is scheduled to vest in eight semi-annual installments over the four-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date. By: Louis A. Bianco, Attorney-in-fact For: Matthew Plunkett 2015-12-23